optic disk edema
Conditions
Interventions
Case series:vitreous injection of Conbercept
Sponsors
the First Medical Center of Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. aged 30-65 years; 2. within 4 weeks; 3. best corrected visual acuity: 0.1~0.8; 4. sign the informed consent and follow up voluntarily according to the specified follow-up time; 5. fundus examination optic disc edema.
Exclusion criteria
Exclusion criteria: 1. Allergy or history of allergy to any ingredient in the test drug; 2. Patients with serious cardiovascular, liver, kidney or hematopoietic diseases, diabetes and hypertension; 3. A history of using other DMT drugs within six months, such as interferon, natabizumab, fdi-720, etc.; 4. Have participated in clinical trials of other new drugs in the recent 3 months; 5. Due to severe mental or language disorders, the researcher cannot complete the clinical trial protocol; 6. The target eye received other anti-vegf treatments within 6 months; 7. The eye has received any piperatanil, sterol, photodynamic therapy, fovea thermal laser therapy; 8. Performed intraocular or periocular operations within 3 months of the target eye, except eyelid operations that do not affect vitreous injection; 9. The eye has undergone the following eye surgery, as well as other submacular surgery or other surgery for CNV; 10. The target eye or the contralateral eye has active eye infection, such as blepharitis, infectious conjunctivitis, keratitis, scleral inflammation, endophthalmitis or repeated infection; 11. With suspected glaucoma, high intraocular pressure, glaucoma and uncontrolled glaucoma; 12. No lens or posterior capsular rupture; 13. Eye tumor; 14. High myopia; 15. Medullated nerve fibers in optic disc; 16. Small concave optic disc; 17. Stale and active uveitis; 18. Other diseases of the retina that may cause impaired vision; 19. Cataracts may develop within the last 6 months and affect vision; 20. Hysteria and false blindness suspected; 21. Patients receiving oral, intramuscular or intravenous therapy for systemic infection; 22. The patient has coagulation mechanism disorder or is taking oral warfarin, bolivar and other similar drugs for anticoagulation therapy; 23. Had used systemic hormone or intrauterine hormone injection 6 months before the visit; 24. A history of surgical procedures within 1 month prior to enrollment, and/or current unhealed wounds, ulcers, fractures, etc.; 25. Has a confirmed systemic immune disease or has any uncontrolled clinical problems; 26. Those who have participated in any drug clinical trial within 3 months prior to screening; 27. The investigator considers it inappropriate to participate in this clinical trial for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCVA; | — |
Countries
China
Contacts
Public ContactShihui Wei
the First Medical Center of Chinese PLA General Hospital
Outcome results
None listed